




T1DX-QI Collaborative Meeting, Pediatrics

January 29, 2026

Agenda

- Welcome and Introductions
- Updates from the Coordinating Center
- Clinical center presentation: Rainbow Babies
- Clinical center presentation: Seattle Children's
- Next meeting: Combined Adult and Pediatrics call,
Tuesday April 14th 3:30-5:00pm EST

TDX-QI Collaborative Centers: 42 Pediatric & 23 Adult



**Find information
about T1DX-QI on the
member website**



Find information about
T1DX-QI data and
benchmarking on the
QI Portal.



2026 ADA Abstracts

Thank you for your contributions to the ADA Scientific Session Abstracts!

1. Correlation Of Minoritized Ethnicity Representation Between Patients And Staff Of Diabetes Centers Involved In T1DX-QI
2. Emerging T1D Screening And Intervention Programs: Insights From 63 Centers In T1DX-QI
3. Dietician FTE Support
4. Center Staffing and Structure/FTE
5. Practice patterns for CGM initiation after diagnosis of Type 1 diabetes in pediatric and adult settings: A T1DX-QI study
6. Common barriers to health equity and factors actively addressed to improve health equity in T1DX-QI
7. Using The Consolidated Framework For Implementation Research (CFIR) To Identify Barriers And Facilitators To Adoption Of A Digital Quality Improvement Portal Across A National T1D Collaborative
8. Update of the T1DX/DPV Analysis
9. IMPROVAID focus groups
10. Baseline Microalbuminuria Screening Rate: Result from T1D Exchange Pediatric Registry
11. Increasing Adoption Of Diabetes Technology Among Adults With T1D In A National Quality Improvement Collaborative
12. Increasing Adoption Of Diabetes Technology Among Children And Youth With T1D: T1DX-QI
13. Advancing Equity In Diabetes Technology: T1DX-QI Multi-Center QI Project Across Adult And Pediatric Centers
14. Operationalizing Screening for Stage 1 and Stage

Annual Clinic Survey Questions, 2026

We are collecting annual survey question proposals now through Friday, May 1, 2026.

Guidelines:

- Please limit to no more than 8 questions per topic
- Questions should be multiple choice
- Ranking and metric tables are suggested
- Free text is discouraged
- Submitters are expected to create an abstract (ADA, ISPAD, etc) on topic
- We highly encourage the development of manuscripts based on these topics

To submit your topics, please
email qi@t1dexchange.org and
cc nrioles@t1dexchange.org and crainey@t1dexchange.org

Topic areas from 2025, for reference

- Clinical Demographics
- Clinic Staffing and Structure
- Teamwork, Targets, Technology and Tight Glycemia
- Dietician (FTE) Support
- Health Equity
- Healthcare Transition
- GLP-1 Use in Children w/T2D
- Economic Impacts
- T1DX-QI Experience

T1DX-QI Learning Session, Save the Date for 2026!

Thank you for joining us in person in 2025!

- Your abstracts and the commentary for the 2025 LS will be published next month in the *Journal of Diabetes*.
- You can find presentations and posters from 2025 on the LS page of the member website.



2026

- November 9th- welcome reception in the evening
- November 10-11 Learning Session
- We look forward to seeing you in San Diego!
- The conference will be hosted at the Westin Bay View.



T1DX-QI 2026-2028 Measures

New 2026-2028 Measures go live on 1/1/2026

- New Smartsheets for the new measurement period will be shared with teams within the next month.
- Data reporting for the new period is requested by 3/31/2026 to begin reporting data for the 1/1/2026+ period
- You can find updates measures on the Member Website: <https://t1dx-qi.t1dexchange.org/measures/>

Quality Improvement (QI) Pediatric Metrics

2022 - 2025	2026 - 2028
<ul style="list-style-type: none"> • A1c <7%; A1c >9% • Median A1c 	<ul style="list-style-type: none"> • A1c <7%; A1c >9% • Median A1c • Median GMI
<ul style="list-style-type: none"> • CGM use • AGP: TIR; Hypo; Hyper 	<ul style="list-style-type: none"> • CGM use • AID use¹ • AGP; TIR >70%; Hypo <4%; Severe Hypo <1%
Bolusing 3x daily by pump or pen	Incretin Mimetic Prescribing
<ul style="list-style-type: none"> • Depression screening: PHQ-2; PHQ-9 • Diabetes Distress 	<ul style="list-style-type: none"> • Depression screening²: PHQ-2; PHQ-9; • Diabetes Distress Screening: PAID-T
DKA Hospitalization and Events	DKA Hospitalization
Social Determinants of Health	Social Drivers of Health: Economics; Transportation; Housing
Transition of care plan	Transition of care plan
Tobacco Use	<ul style="list-style-type: none"> • Severe Hypo Hospitalization • Severe Hypo Events³
AID Use	<ol style="list-style-type: none"> 1. Counting pump use and AID use, combined, assuming that pump is AID use. 2. For the measurement period 3. Events requiring external assistance, including PROs.

Quality Improvement (QI) Metrics 2026 - 2028

Adult Priority Measures

- 1) A1c <7%; A1c >9%; Median A1c
- 2) CGM use
- 3) AID use
- 4) AGP; TIR >70%; Hypo <4%;Severe Hypo <1%
- 5) Food insecurity
- 6) DKA Hospitalization
- 7) Severe Hypo Hospitalization
- 8) Severe Hypo Event

Pediatric Priority Measures

- 1) A1c < 7%; A1c >9%; Median A1c
- 2) CGM use
- 3) AID use
- 4) AGP; TIR >70%; Hypo <4%;Severe Hypo <1%
- 5) Food insecurity
- 6) DKA Hospitalization
- 7) Severe Hypo Hospitalization
- 8) Severe Hypo Event
- 9) Transition Plan

QI Metrics (Pediatrics) 2022 - 2025

- 1) A1c < 7%; A1c >9%
- 2) Median A1c
- 3) CGM use
- 4) Depression screening: PHQ-2; PHQ-9
- 5) AGP: TIR, Hypo, Hyper
- 6) Bolusing 3x daily by pump or pen
- 7) DKA
- 8) Transition of care plan
- 9) SDOH
- 10) Tobacco use
- 11) Diabetes distress
- 12) Automated Insulin Delivery Use

Updated QI Metrics (Pediatrics) 2026 - 2028

- 1) A1c < 7%; A1c >9%; Median A1c
- 2) CGM use
- 3) AID use
- 4) AGP; TIR >70%; Hypo <4%;Severe Hypo <1%
- 5) Food insecurity
- 6) DKA Hospitalization
- 7) Severe Hypo Hospitalization
- 8) Severe Hypo Event
- 9) Transition Plan
- 10) Median GMI
- 11) Diabetes Distress (PAID-T)
- 12) Depression screening: PHQ-2; PHQ-9
- 13) Incretin Mimetic Prescribing
- 14) Social Drivers of Health: Economics; Transportation; Housing

Screening and Monitoring Update

T1DX-QI convened a *Beta Cell Preservation Workgroup* in November 2025. The group has been tasked with identifying how we can operationalize new workflows to:

- 1) Track and monitor Stage 1, Stage 2, and Stage 3 diabetes
- 2) Prioritize measures for diabetes screening, monitoring, and prevention and incorporating them into the T1DX-QI data specification
- 3) Be poised for teplizumab labelling for Stage 3 diabetes use (anticipated this winter/spring.)

Key outcomes from the Workgroup

- 1) A white paper has been developed and will be available for dissemination by 2/23 on the T1D Exchange website
- 2) A manuscript, summarizing the elements of the white paper, is in development and will be submitted to JCEM in February
- 3) New measures for screening and monitoring will be presented to the Data Science Committee for review and incorporation into the data spec in 2026



T1D
Exchange



Center Presentation: Rainbow Babies and Children's, University Hospitals

Rainbow Babies and Children's, University Hospitals

- **Multidisciplinary Team Members**
- Ped Endo MD: 11*
- PNP: 1 (new)
- Endo Fellows: 4
- Registered Nurses (including CDES): 7
- Social Worker: 2
- Psychologist: 1 (0.5 FTE Child/Adol)
- Research Team: 2
- Medical Assistant: 3
- Diabetes Navigator: 1

*including partial FTE of a med/peds endocrinologist for transition

Volume and Demographics

~1000 patients with T1D, including our young adults and new onset youth

Newly diagnosed patients per year: ~85

Insurance: ~ 40% public

Race/Ethnicity

~70% white

~20% black

~5% Hispanic

~5% Other

Contact Names

Site PI:

Anna Neyman, MD

Anna.Neyman2@UHhospitals.org

Site Coordinator:

Quiana Howard, MSN, RN-BC

Quiana.Howard@UHhospitals.org

Team Members

Jamie Wood, MD


Nadine Houmani, MD

Anna Kessler, RN, BSN

Depression Screen QI Project

- **We know that mental health is an important component of both well being and glycemic control.**
- The **ADA and ISPAD** re-iterate the importance of depression screening to be able to intervene when needed as early detection can lead to earlier treatment and decrease potential adverse effects.
- **In 2023 our depression screen percentage decreased significantly to 50.9%.**
- At the same time, our EMR system was in the process of changing, and thus this was the moment to intervene to improve this important clinical metric.
- **Our goal was to increase our depression screening to >70% within 6 months.**


Depression Screening QI Project



* Patient is ≥ 12 years old, and is eligible for a depression screen, with capacity to complete the survey.

Education

- Created a **standardized clinical pathway** for whom to screen, when to screen and what to do with the results
- Worked as **a multidisciplinary team with our providers, diabetes nurses, and social work**



**Scored Severe (20-27) or
Endorsing SI or
HI: Referred to Emergency
department from clinic for
Psychiatric Evaluation.**

*can call on call SW if after
hours and needed

***Can provide 988 number
(text or call): Suicide and
Crisis Lifeline**

*Provided mobile crisis
number to patient during
clinic visit. **Mobile crisis
8664371821 or
2166236888 or Text:
"4Hope" to 741-741".**

***Epic Message sent to
Social Work to link to
appropriate services within
24-48 hours, can try to
reach out more urgently as
well**

***Follow up with PHQ at
next diabetes clinic visit.**

PHQ-9 result

**Scored Moderately Severe
(15-19): (not suicidal)**

*Provided mobile crisis
number to patient during
clinic visit.

**Mobile crisis 8664371821 or
2166236888 or Text: "4Hope"
to 741-741".**

*Epic message to Social Work
to link to appropriate services
within 24-48 hours (**send a
Epic message to both Alyssa
and Caren with red flag to
mark urgent**)

*May need referral to
Emergency department from
clinic for Psychiatric
Evaluation if deemed
necessary by Social Worker or
provider.

***Follow up with PHQ at next
diabetes clinic visit.**

**Scored Moderate
(10-14):**

***Epic message sent
to Social Work to
follow up, assess and
link to appropriate
services within 24-48
hours.**

***Follow up with PHQ
at next diabetes clinic
visit.**

Scored Mild (5-9)

***Epic message sent
to Social Work to
follow up, assess and
link to appropriate
services if needed.**

***Follow up with PHQ
at next diabetes clinic
visit.**

•Scored none (0-4):

**-Score 0 = rescreen in 1 year
-Score 1-4: rescreen in 6 months**


Education

Provided

Educational Sessions

Informational Emails

Handouts



This was provided by both our physician team and our diabetes nurse QI champion

Informational Handout

Depression Screening: PHQ2/PHQ9

- Screen any patient 12 years and older, as developmentally appropriate
- Screening should be completed once every calendar year
 - You can “hover to discover” over the last screens answers to discover the date it was entered
- You do not need to screen if patient is actively receiving mental health treatment
 - If there is a known mental health history but patient is not actively receiving treatment, they should still be screened
- If PHQ score is over 5
 - Please refer to flow sheet for next steps
- If PHQ score is under 5 patient to rescreen in 6-12 months.
- Caren and Alyssa have a “social work” file in the Sdrive that they update with resources

Please see below for the Depression Algorithm (Flow Sheet)

EMR

- **Created the Diabetes Tab**
 - Created and later edited for clarity and to include our screening questions, as listed below:

Screens

Eye Exam

Not Applicable Yes   

Labs

Flu Shot


Not Applicable Yes   

Depression Screen

Not Applicable Yes   

Counseling

Not applicable Currently in counseling Referred to counseling   

EMR

Worked with the Epic team to **optimize the current Epic flow** for how to access the depression screen

- PHQ-2/PHQ-9 right below in the same tab

PHQ-9

+ New Reading

Over the past 2 weeks, how often have you been bothered by any of the following problems?

	Last Filed Value
Little interest or pleasure in doing things	Not at all ⓘ ◀◀
Feeling down, depressed, or hopeless	Not at all ⓘ ◀◀
Patient Health Questionnaire-2 Score	0 ⓘ ◀◀

EPIC dot phrase

Created an **Epic SmartPhrase** that automatically pulls the results and in addition has a drop down with the plan for each score

Severity measure for depression (PHQ9 for Adolescents-Adapted) Total or Prorated Raw Score= Patient Health Questionnaire-9 Score: 14

Severity of Depressive disorder or episode falls under the following category, with plan:

phq9plan ▾

when you click on, the below options, appear and you click on the right one

Severity of Depressive disorder or episode falls under the following category, with plan:

phq9plan ▾

- None (0): Will follow up with PHQ-A in one year
- None (1-4): Will follow up with PHQ-A in 6 months
- Mild (5-9): Message sent to Social Work to follow up, assess and link to appropriate services if needed. Follow up with PHQ-A at next diabetes clinic visit.
- Moderate (10-14), no SI/HI: Message sent to Social Work to follow up, assess and link to appropriate services. Goal for SW to follow-up within 48 hours as able. Follow up with PHQ-A
- Moderately Severe (15-19), no SI/HI: Provided mobile crisis number to patient during clinic visit. Mobile crisis 8664371821 or 2166236888 or Text: "4Hope" to 741-741". Suicide and C
- Severe (20-27) or Endorsing SI or HI: Referred to Emergency department from clinic for Psychiatric Evaluation. Provided mobile crisis number to patient during clinic visit. Mobile cris


Methods to assess intervention

- Three clinic days from three different clinic sites were reviewed every month to analyze our percentage of eligible patients that had appropriate depression screens done (PHQ-2/PHQ-9).
- We used our PDSA cycles to create interventions and then used this data to analyze and help guide further changes.

Results

- **Baseline**
 - Our 2023 baseline was 51%
 - Our baseline data in the 2 months prior to starting the QI project using our 3-site clinic analysis method was **63%**.
- **After the initial PDSA cycle:**
 - We quickly increased our percentage to meet our goal
- **We had some decreases in depression screening rates, which prompted further analysis and interventions. After these further PDSA cycles**
 - Our percentage rose again
 - **Our most recent months average is 90%**
 - Our relative increase from baseline was 31.7%

Eligible T1D Patients Screened



Conclusions

- Using targeted education with a multidisciplinary approach and harnessing the EMR helped to increase our diabetes depression screening rates and exceed our goal for this important clinical care metric.

Next steps:

- Project has transitioned to maintenance phase
 - maintain depression screening levels > 80%
- Assess post-intervention results (for example, was pathway followed for positive screen)

AID QI Project

Improve utilization of AID technology


Nadine Houmani, Quiana Howard, Anna Kessler, Sarah MacLeish,
Anna Neyman

Background

- T1Dx Primary Aim: increase proportion of patients achieving glycemic targets in an equitable manner
- On review of our pediatric population data at our site, only ~1/4 of our T1D population reach goal of HbA1C <7%
- We know that AID use leads to improved HbA1c and that there is a gap in AID use

Baseline Statistics

HCLS use



	total (%)	NHW (%)	NHB (%)
Median (baseline) Jan-Oct	69.5	76	52

AID QI project

Our baseline data shows median 69.5% AID use in the past 10 months (Jan-Oct 2025).

We did a subgroup analysis, including markers such as insurance status, race/ethnicity to review if any subsets have an AID use <60%.

Our NHB pediatric patients with T1D have median of 52% AID use.


Aims:

1. Increase Total AID utilization by at least 5% in 12 months.

 Increase from baseline $69.5\% \geq 73\%$


2. In any cohort that has median AID use <60%, increase AID utilization by 10% in 12 months.

 In our NHB youth increase AID utilization from baseline $52\% \geq 57\%$





Questions



Center Presentation: Seattle Children's Hospital



Utilizing Quality Improvement to Implement and Standardize Peripheral Neuropathy Screening in Pediatric Patients with Diabetes

Jessica Johnson, ARNP, DNP, FNP-BC, CDCES

01/29/2026



Seattle Children's®

Background

Research

- SEARCH: Diabetic Peripheral Neuropathy (DPN) prevalence - 7% Type 1 Diabetes & 22% Type 2 Diabetes (T2D)
- TODAY Study: Youth w/T2D show evidence of DPN early

Insights

- The high rates of DPN among youth with diabetes are a cause of concern and suggest a need for early screening and better risk factor management



About Us: Seattle Children's Hospital Diabetes Center

Our Patients

- 2932 w/Diabetes
- 469 w/T2D
- 51% NHW, 46% male
- 89% English preferred language
- 69% public insured

Our Staff

- 21 Physicians
- 12 APPs
- 19 RNs
- 2 Psychologists
- 1 Athletic Trainer
- Multidisciplinary Team
- MA, RD, SW



About Us: Seattle Children's Hospital Diabetes Center



Seattle – Sand Point Clinic
(40% of all diabetes patients)

Everett – (30%)

Bellevue – (10%)

Federal Way – (16%)

**Olympia
Wenatchee
Tri-Cities**



Available Knowledge



Seattle Children's®

American Diabetes Association Standards of Care

- T2D Diabetes Foot Exam at diagnosis and annually thereafter

Comprehensive Diabetes Foot Exam (DFE)

- Inspection
- Assessment of foot pulses
- Pinprick or temperature sensation
- 10-g monofilament sensation
- Vibration sensation 128-Hz tuning fork
- Ankle reflex tests
- Assessment of neuropathic pain
- Prevention focused on achieving glycemic goals
- Foot care education
- Referral to Neurology or Pain Specialist

How are we doing at SCH?

Chart Audit: Care Gaps

- 0% had DFE
- 0% provided foot care education
- 7.8% visual assessment

Clinical Care & Internal Reports


- Lack DFE supplies in clinic
- Lack foot care education materials
- DFE not part of usual care
- 0 Tracking of DFE



SMART Aim

To increase annual peripheral neuropathy screening in youth with type 2 diabetes from 0% to 20% at Sand Point Clinic from July 2025 to December 2025





Aim

Primary drivers

Change ideas

Team roles and responsibilities not in place.

Staff education of DFE process

Providers unfamiliar with DFE

Provider training on DFE & MNSI

Culturally & linguistically diverse population - LOE

Create & translate Pt Infographic materials

Patient unfamiliar with DFE

Create & translate pt education materials

No patient education materials on DFE or foot care

Create DFE supply kits

No DFE supplies in clinic

Develop Smar Phrases for standardized documentation

No system in place for identifying patients needing DFE.

Use Clinic Prep tab to alert patients needing DFE during clinic visit

No standardized process or documentation performing DFE

Care gaps or BPA to alert pts due for DFE

Line item added in flow sheet to track last DFE

— = change ideas not implemented

Intervention #1

Tools: Supply Kit

Timeline: Implemented at start of project



Reflex hammer
128 hertz tuning fork
10-gram monofilament



Seattle Children's®

Intervention #2

Tools: Infographic

Timeline: Implemented at start of project



Seattle Children's®

 **What to Expect During Your Diabetes Foot Exam**

Why This Matters:
Foot exams help us catch early signs of nerve damage (neuropathy) or circulation problems that can lead to serious complications if left untreated.

Even if you feel fine, checking regularly is an important part of your diabetes care.

Your foot exam will include:

1. Symptoms questionnaire
2. Visual inspection
3. Checking circulation
4. Sensation testing

The infographic is divided into four quadrants. Top-left: 'Symptom Questionnaire' with an icon of a clipboard with three checkmarks. Top-right: 'Visual Inspection' with an icon of a foot inside a blue circle. Bottom-left: 'Checking Circulation' with an icon of a hand holding a foot. Bottom-right: 'Testing Sensation' with an icon of a foot next to a tuning fork.

Intervention #3a

Tools: Michigan Neuropathy Screening Instrument (MNSI) Questionnaire

Timeline: Implemented at start of project

A score of 7 or more indicates a positive screening.

Diabetes Foot Exam Questionnaire

1. Are your legs and/or feet numb?	Yes= 1
2. Do you ever have any burning pain in your legs and /or feet?	Yes= 1
3. Are your feet too sensitive to touch?	Yes= 1
4. Do you get muscle cramps in your legs and/or feet?	Yes/No -
5. Do you ever have any prickling feelings in your legs or feet?	Yes= 1
6. Does it hurt when the bed covers touch your skin?	Yes= 1
7. When you get into the tub or shower, are you able to tell the hot water from the cold	No= 1
8. Have you ever had an open sore on your foot?	Yes= 1
9. Has your doctor ever told you that you have diabetic neuropathy?	Yes= 1
10. Do you feel weak all over most of the time?	Yes/No -
11. Are your symptoms worse at night?	Yes= 1
12. Do your legs hurt when you walk?	Yes= 1
13. Are you able to sense your feet when you walk?	No= 1
14. Is the skin on your feet so dry that it cracks open?	Yes= 1
15. Have you ever had an amputation?	Yes= 1

Score: /13

Score of 7 or more indicates a positive screening.
Consider referring positive neuropathy screenings to neurologist.



Intervention #3b

Tools: MNSI Exam

Timeline: Implemented at start of project with modifications as tests of change.

Diabetes Foot Exam		
	Right	Left
Appearance of feet: (Deformity, dry skin, callus, infection, fissure)	Normal= 0	Abnormal= 1
Ulceration	Absent= 0	Present= 1
Ankle Reflexes	Absent= 1	Present/reinforced= 0.5
Vibration perception at great toe	Absent= 1	Decreased= 0.5
Monofilament	Absent= 1	Absent= 1
Foot pulses: (0-4+)	Dorsalis pedis: pedal pulses Posterior tibial: pedal pulses	Dorsalis pedis: pedal pulses Posterior tibial: pedal pulses
Temperature Sensation	Temperature sensation	Temperature sensation

Score: ***

Score of greater than 2 is considered a positive exam.
*Consider referring positive neuropathy screenings to neurology.
Consider referring non-neuropathy related foot appearance abnormalities to PCP treatment or possible podiatry referral per PCP.



Score of greater than 2 is considered a positive exam.

Intervention #4

Tools: Education Materials


Timeline: Implemented at start of project with modifications as test of change.



- Diabetes Foot Care Tips - PE4447                                          <img alt="link icon" data-bbox="4940 865

Aim Run Chart (n=126)

— = values
— = median
- - - = goal



Screening Results

Overall screening rates demonstrated DPN positivity rate of 1.6 % (n= 1 of 63) for patients with T1D and a positivity rate of 11.9% (n= 5 of 42) for patients with T2D. This is consistent with results from SEARCH report of a higher prevalence of DPN in youth with T2D (22%) than those with T1D (7%).



Questionnaire Findings

Discussion Points:

Are your legs and/or feet numb?

Do you ever have burning pain in your legs and/or feet?

Do you get muscle cramps in your legs and/or feet?

Do you ever have prickling feelings in your legs or feet?

Have you ever had open sores on your foot?

Lessons Learned:

Was the appearance of feet abnormal?



Conclusion

Sustainability & Spread

Low cost to implement

Steps embedded into daily workflow

Lessons Learned

Staff education drove quality improvement

Low-cost changes can improve diabetes care

Use of Epic Tools to enable standardization of documentation

Next steps

Clinic-wide scaling & training

Addition of DFE supplies to recurring inventory

Optimizing EHR for tracking and health maintenance alerts

Ongoing process improvement w/new pilot QI



Thank You!



Seattle Children's®

